Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. HOOD
9. DFTX
10. IBM

Go back to Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020

February 8, 2020 3:06 PM EST

-- Robust efficacy with evidence of a dose response ---- 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks -- -- 4/6 patients rescue-injection-free in cohort 2 (lower dose) at 24 weeks --

-- Company to host and webcast a discussion with key opinion leaders Sunday, February 9, at 10:00 am EST --

REDWOOD CITY, Calif., Feb. 08, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:... More